Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Saad, F. del Rosario, P. Clarke, Noel W
Saad, F.
del Rosario, P.
Clarke, Noel W
Citations
Altmetric:
Abstract
Authors
Description
Date
2024
Publisher
Collections
Keywords
Type
Other
Citation
Saad F, del Rosario P, Clarke NW. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. EUROPEAN UROLOGY. 2024 JUN;85(6):e178-e9.